Phosphoinositide 3-kinase signalling - Which way to target?

Trends in Pharmacological Sciences

Volumn 24, Issue 7, 2003, Pages 366-376

  Wymann, Matthias P ^a   Zvelebil, Marketa ^b   Laffargue, Muriel ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; IMATINIB; ISOENZYME; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; TEMSIROLIMUS; TRASTUZUMAB; WORTMANNIN; ENZYME INHIBITOR; PROTEIN SUBUNIT;

ALLERGY; APOPTOSIS; CANCER; CARDIOVASCULAR PARAMETERS; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC INFLAMMATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME SUBUNIT; HEART FAILURE; HUMAN; METABOLIC REGULATION; NONHUMAN; NUTRIENT UPTAKE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; PHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CELLS, CULTURED; ENZYME ACTIVATION; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION;

EID: 0042734621     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00163-9     Document Type: Review

References (87)

1. Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 296:2002;1655-1657.
2. Wymann M.P., Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim. Biophys. Acta. 1436:1998;127-150.
3. Vanhaesebroeck B., et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70:2001;535-602.
4. Hirsch E., et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science. 287:2000;1049-1053.
5. Sasaki T., et al. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science. 287:2000;1040-1046.
6. Li Z., et al. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science. 287:2000;1046-1109.
7. Laffargue M., et al. Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity. 16:2002;441-451.
8. Crackower M.A., et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 110:2002;737-749.
9. Naga Prasad S.V., et al. Phosphoinositide 3-kinase regulates β2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/β-arrestin complex. J. Cell Biol. 158:2002;563-575.
10. Yamada K.M., Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci. 114:2001;2375-2382.
11. Itoh M., et al. Role of Gab1 in heart, placenta, and skin development and growth factor- and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation. Mol. Cell. Biol. 20:2000;3695-3704.
12. Gu H., et al. Essential role for Gab2 in the allergic response. Nature. 412:2001;186-190.
13. Sattler M., et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 1:2002;479-492.
14. Murphy M.A., et al. Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol. Cell. Biol. 18:1998;4872-4882.
15. Bachmaier K., et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature. 403:2000;211-216.
16. Rickert R.C., et al. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature. 376:1995;352-355.
17. Yamazaki T., et al. Essential immunoregulatory role for BCAP in B cell development and function. J. Exp. Med. 195:2002;535-545.
18. Zhang W., et al. Essential role of LAT in T cell development. Immunity. 10:1999;323-332.
19. Brazil D.P., Hemmings B.A. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci. 26:2001;657-664.
20. Leslie N.R., et al. Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem. Rev. 101:2001;2365-2380.
21. Itoh T., Takenawa T. Phosphoinositide-binding domains: Functional units for temporal and spatial regulation of intracellular signalling. Cell. Signal. 14:2002;733-743.
22. Kozma S.C., Thomas G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioessays. 24:2002;65-71.
23. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:2002;489-501.
24. Alvarez B., et al. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature. 413:2001;744-747.
25. Innocenti M., et al. Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1. J. Cell Biol. 160:2003;17-23.
26. Welch H.C., et al. P-Rex1, a PtdIns(3,4,5)P3- and Gβγ- regulated guanine-nucleotide exchange factor for Rac. Cell. 108:2002;809-821.
27. Wymann M.P., et al. Lipids on the move: phosphoinositide 3-kinases in leukocyte function. Immunol. Today. 21:2000;260-264.
28. Stephens L., et al. Roles of PI3Ks in leukocyte chemotaxis and phagocytosis. Curr. Opin. Cell Biol. 14:2002;203-213.
29. Bi L., et al. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274:1999;10963-10968.
30. Bi L., et al. Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase. Mamm. Genome. 13:2002;169-172.
31. Lawlor M.A., et al. Essential role of PDK1 in regulating cell size and development in mice. EMBO J. 21:2002;3728-3738.
32. Terauchi Y., et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat. Genet. 21:1999;230-235.
33. Ueki K., et al. Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U. S. A. 99:2002;419-424.
34. Araki E., et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature. 372:1994;186-190.
35. Withers D.J., et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 391:1998;900-904.
36. Cho H., et al. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276:2001;38349-38352.
37. Cho H., et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science. 292:2001;1728-1731.
38. Di C.A., et al. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19:1998;348-355.
39. Stambolic V., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:1998;29-39.
40. Liliental J., et al. Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr. Biol. 10:2000;401-404.
41. Malliri A., et al. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature. 417:2002;867-871.
42. Helgason C.D., et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12:1998;1610-1620.
43. Clement S., et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature. 409:2001;92-97.
44. Liao X.C., Littman D.R. Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk. Immunity. 3:1995;757-769.
45. Turner M., et al. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity. 7:1997;451-460.
46. Doody G.M., et al. Signal transduction through Vav-2 participates in humoral immune responses and B cell maturation. Nat. Immunol. 2:2001;542-547.
47. Fruman D.A., et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science. 283:1999;393-397.
48. Suzuki H., et al. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Science. 283:1999;390-392.
49. Khan W.N., et al. Defective B cell development and function in Btk-deficient mice. Immunity. 3:1995;283-299.
50. Wang D., et al. Phospholipase Cγ2 is essential in the functions of B cell and several Fc receptors. Immunity. 13:2000;25-35.
51. Okkenhaug K., et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 297:2002;1031-1034.
52. Jou S.T., et al. Essential, Nonredundant Role for the Phosphoinositide 3-Kinase p110delta in Signaling by the B-Cell Receptor Complex. Mol. Cell. Biol. 22:2002;8580-8591.
53. Clayton E., et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med. 196:2002;753-763.
54. Servant G., et al. Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science. 287:2000;1037-1040.
55. Hannigan M., et al. Neutrophils lacking phosphoinositide 3-kinase gamma show loss of directionality during N-formyl-Met-Leu-Phe-induced chemotaxis. Proc. Natl. Acad. Sci. U. S. A. 99:2002;3603-3608.
56. Sasaki T., et al. Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kγ Nature. 406:2000;897-902.
57. Barbier M., et al. Tumour biology. Weakening link to colorectal cancer? Nature. 413:2001;796.
58. Young L.H., et al. Wortmannin, a potent antineutrophil agent, exerts cardioprotective effects in myocardial ischemia/reperfusion. J. Pharmacol. Exp. Ther. 295:2000;37-43.
59. Cascieri M.A. The potential for novel anti-inflammatory therapies for coronary artery disease. Nat. Rev. Drug Discov. 1:2002;122-130.
60. Arcaro A., Wymann M.P. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J. 296:1993;297-301.
61. Yano H., et al. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J. Biol. Chem. 268:1993;25846-25856.
62. Vlahos C.J., et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269:1994;5241-5248.
63. Wymann M.P., et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 16:1996;1722-1733.
64. Walker E.H., et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell. 6:2000;909-919.
65. Baggiolini M., et al. Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. Exp. Cell Res. 169:1987;408-418.
66. Guba M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8:2002;128-135.
67. Shi Y., et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 62:2002;5027-5034.
68. Sadhu C., et al. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J. Immunol. 170:2003;2647-2654.
69. Shtiegman K., Yarden Y. The role of ubiquitylation in signaling by growth factors: implications to cancer. Semin. Cancer Biol. 13:2003;29-40.
70. Fang D., et al. Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J. Biol. Chem. 276:2001;4872-4878.
71. Stephens L.R., et al. The Gβγ sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell. 89:1997;105-114.
72. Brock C., et al. Roles of G{β}{γ} in membrane recruitment and activation of p110{gamma}/p101 phosphoinositide 3-kinase {gamma}. J. Cell Biol. 160:2003;89-99.
73. Pacold M.E., et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell. 103:2000;931-943.
74. Suire S., et al. Activation of phosphoinositide 3-kinase gamma by Ras. Curr. Biol. 12:2002;1068-1075.
75. Rolli V., et al. Amplification of B Cell Antigen Receptor Signaling by a Syk/ITAM Positive Feedback Loop. Mol. Cell. 10:2002;1057-1069.
76. Nishida K., et al. Gab-family adapter proteins act downstream of cytokine and growth factor receptors and T- and B-cell antigen receptors. Blood. 93:1999;1809-1816.
77. Wange R.L. LAT, the linker for activation of T cells: a bridge between T cell-specific and general signaling pathways. Sci STKE. 2000:2000;RE1.
78. Wilson B.S., et al. High resolution mapping of mast cell membranes reveals primary and secondary domains of Fc(epsilon)RI and LAT. J. Cell Biol. 154:2001;645-658.
79. Burgering B.M., Kops G.J. Cell cycle and death control: long live Forkheads. Trends Biochem. Sci. 27:2002;352-360.
80. Shiojima I., Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 90:2002;1243-1250.
81. Fruman D.A., Cantley L.C. Phosphoinositide 3-kinase in immunological systems. Semin. Immunol. 14:2002;7-18.
82. Hirsch E., et al. Resistance to thromboembolism in PI3Kγ-deficient mice. FASEB J. 15:2001;2019-2021.
83. Tamemoto H., et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature. 372:1994;182-186.
84. Ellmeier W., et al. Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk. J. Exp. Med. 192:2000;1611-1624.
85. Shinohara M., et al. SWAP-70 is a guanine-nucleotide-exchange factor that mediates signalling of membrane ruffling. Nature. 416:2002;759-763.
86. Ji Q.S., et al. Essential role of the tyrosine kinase substrate phospholipase C-γ1 in mammalian growth and development. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2999-3003.
87. Takeshita S., et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat. Med. 8:2002;943-949.